
Arcutis After The Double: Hypergrowth Peaks, Compounding Remains
ARQT • NASDAQ
Unlock comprehensive alternative data signals to make better investment decisions

Track website visits, page views, unique visitors, and engagement metrics over time to gauge online interest and brand strength.

Monitor Twitter follower growth, engagement rates, and social media presence to understand brand reach and community sentiment.

Analyze TikTok follower trends and viral content performance to measure youth demographic appeal and cultural relevance.

Track Facebook page likes, comments, shares, and post engagement to assess community interaction and brand loyalty.

Monitor Instagram follower growth, engagement rates, and visual content performance across demographics.

Track YouTube channel growth, video views, and subscriber engagement to measure content marketing effectiveness.

Monitor LinkedIn company page followers and professional network growth to assess B2B brand strength and talent attraction.

Track open job positions and hiring trends as a leading indicator of company expansion, contraction, or strategic shifts.

Monitor employee headcount changes on LinkedIn to gauge organizational growth, restructuring, or cost-cutting measures.

Analyze sentiment scores from Reddit discussions to understand retail investor mood and potential price momentum.

Track daily news mentions across major publications to measure media attention, PR effectiveness, and market awareness.

View key financial metrics including Revenue, Net Income, EPS, Free Cash Flow, EBITDA, and Total Assets. Access 2-year quarterly charts for Revenue & Income and Free Cash Flow trends.

Analyze technical indicators including 50-day Simple Moving Average (SMA) with price overlay and Relative Strength Index (RSI) charts.
TrendEdge provides tools and data for research and educational purposes only and does not provide investment advice or personal recommendations.
You don't hold ARQT in your mock portfolio yet.
Arcutis Biotherapeutics has shown strong growth in its financial performance. The company's revenue of $44.8M, up by 45% from the previous quarter and 230.9% year over year, indicates a solid trend of increasing sales. Their gross profit at $39.3M is also on an upward trajectory, with a rise of 43.3% from the previous quarter and a significant increase of 254.2% YoY. However, their operating income is negative at -$39.1M but it improved by 22% QoQ and by 36.1% YoY which shows that they are effectively managing their expenses to improve profitability over time.
The stock price for Arcutis Biotherapeutics has been performing well with an increase of 27.8% in the last month, and an impressive jump of 420.1% YoY indicating strong investor confidence in the company's prospects despite its negative PE ratio (-7.60) and EPS (-1.67). The RSI value stands at around mid-range (66), suggesting that the stock is neither oversold nor overbought while the stock's price being above its 200-day moving average ($9.75) implies positive momentum.
The alternative data signals present mixed results for Arcutis Biotherapeutics' future prospects as web traffic numbers have increased MoM but decreased YoY indicating inconsistent interest online towards the company.The lack of job openings could suggest cost-cutting measures or simply no need for expansion currently.Employee sentiment regarding business outlook appears neutral which may not be enough to drive significant changes in stock performance.Finally,the social media followers count shows growth on Twitter but a slight decline on Facebook,indicating mixed sentiment among the company's social media audience.
In conclusion,the analysis of Arcutis Biotherapeutics' stock is neutral to slightly bullish.The company's strong revenue and gross profit growth,along with its improving operating income and positive stock price momentum are promising signs.However,the negative PE ratio,EPS and mixed alternative data signals suggest some caution is warranted.
Our AI Score rates companies on a scale from 0 to 10, based on alternative data points such as web traffic, app downloads, and job postings — combined with financial health indicators and technical signals.
Key moves vs recent baseline (last day / last week)
Plain-English summary of the biggest drivers (informational)
Potential risk factors to review
Based on earnings timing, volatility, liquidity and crowd activity. Informational signals only — not investment advice.
Reassess your thesis if any of these occur: